Cart
sales@molnova.com
EPAC 5376753
CAS No. 302826-61-5
EPAC 5376753( 5-{[5-(2,4-dichlorophenyl)furan-2-yl]methylidene}-2-thioxodihydropyrimidine-4,6(1H,5H)-dione )
Catalog No. M26202 CAS No. 302826-61-5
EPAC 5376753 is an allosteric inhibitor of EPAC1 with an IC50 of 4 μM in Swiss 3T3 cells.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 195 | Get Quote |
|
| 10MG | 284 | Get Quote |
|
| 25MG | 479 | Get Quote |
|
| 50MG | 692 | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameEPAC 5376753
-
NoteResearch use only, not for human use.
-
Brief DescriptionEPAC 5376753 is an allosteric inhibitor of EPAC1 with an IC50 of 4 μM in Swiss 3T3 cells.
-
DescriptionEPAC 5376753 is an allosteric inhibitor of EPAC1 with an IC50 of 4 μM in Swiss 3T3 cells.(In Vitro):EPAC 5376753 decreases the conformational changes of EPAC necessary for its activation. EPAC 5376753 inhibits EPAC signaling in cells and EPAC-mediated migration in fibroblasts.
-
In VitroEpac is a key mediator of cAMP signaling. EPAC 5376753, the thiobarbituric acid modification of 5225554, has a greater ability to decrease the conformational changes of Epac necessary for its activation and to inhibit Epac signaling in cells. 5376753 selectively inhibits Epac-mediated migration in fibroblasts.
-
In Vivo——
-
Synonyms5-{[5-(2,4-dichlorophenyl)furan-2-yl]methylidene}-2-thioxodihydropyrimidine-4,6(1H,5H)-dione
-
PathwayGPCR/G Protein
-
TargetcAMP
-
RecptorP-gp
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number302826-61-5
-
Formula Weight367.2
-
Molecular FormulaC15H8Cl2N2O3S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESClc1ccc(-c2ccc(C=C3C(=O)NC(=S)NC3=O)o2)c(Cl)c1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Hongzhi Zhang, et al. Anti-tumor Efficacy of Phellamurin in Osteosarcoma Cells:Involvement of the PI3K/AKT/mTOR Pathway. Eur J Pharmacol. 2019 Sep 5;858:172477.
molnova catalog
related products
-
ESI-05
ESI-05 is a specific EPAC2 (exchange protein directly activated by cAMP 2) antagonist (IC50: 0.4 μM). ESI-05 inhibits cAMP-mediated activation of EPAC2, as well as EAPC2, mediated Rap1 activation.
-
ESI-09
ESI-09 is a specific exchange protein directly activated by cAMP (EPAC) inhibitor with IC50 of 3.2 μM and 1.4 μM for EPAC1 and EPAC2, respectively.
-
ESI-08
ESI-08 is an effective antagonist of EPAC2 with an IC50 of 8.4 μM. ESI-08 selectively blocks cAMP-induced EPAC activation but not cAMP-mediated PKA activation.
